Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Volume 28, Issue 3
  5. Article
Volume 28, Issue 3
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Purpose

To systematically evaluate the relationship between cutaneous immune-related adverse events (cirAEs) and the efficacy of PD-1/PD-L1 in the treatment of non-small cell lung cancer (NSCLC) and to provide an evidence-based reference for the clinical application of PD-1/PD-L1 and safety evaluation.

Methods

Electronic databases (PubMed, Embase, Medline, Web of Science, and the Cochrane Library) were screened systematically to collect prospective or retrospective cohort studies on the correlation between cirAEs and efficacy of PD-1/PD-L1 in the treatment of NSCLC.

Results

A total of 3514 participants were included in 13 cohort studies (enclosing an ambidirectional cohort study). Outcomes revealed that compared with those patients with non cirAEs, patients suffering cirAEs were associated with significantly higher objective response rate (ORR) [risk ratio (RR): 1.74, 95% confidence interval (CI): 1.42–2.14, 0.00001], longer progression-free survival (PFS) [RR: 0.52, 95% CI: 0.45–0.60, 0.00001], and longer overall survival (OS) [RR:0.46, 95% CI: 0.38–0.56]. Sensitivity analyses through the exclusion of one study at a time did not significantly influence the outcomes, indicating that the meta-analysis results were relatively robust. Furthermore, subgroup analyses revealed consistent results in the study design (prospective or retrospective cohort studies), as well as in the endpoint results (PFS and OS) of Kaplan–Meier curves or Cox proportional hazards regression for evaluable patients.

Conclusion

Currently, evidence reveals that cirAEs development may be associated with a good prognosis and can be an early predictor of the efficacy of PD-1/PD-L1 in the treatment of NSCLC patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073267261231106093845
2024-01-22
2025-04-02

  • From This Site

    /content/journals/cchts/10.2174/0113862073267261231106093845
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. MolinerP. LupónJ. de AntonioM. DomingoM. Santiago-VacasE. ZamoraE. CedielG. SantesmasesJ. Díez-QuevedoC. TroyaM.I. BoldóM. AltmirS. AlonsoN. GonzálezB. NúñezJ. Bayes-GenisA. Trends in modes of death in heart failure over the last two decades: Less sudden death but cancer deaths on the rise.Eur. J. Heart Fail.201921101259126610.1002/ejhf.1569 31359563
     [Google Scholar]
  3. LuoY.H. ChiuC.H. Scott KuoC.H. ChouT.Y. YehY.C. HsuH.S. YenS.H. WuY.H. YangJ.C.H. LiaoB.C. HsiaT.C. ChenY.M. Lung Cancer in Republic of China.J. Thorac. Oncol.202116451952710.1016/j.jtho.2020.10.155 33781442
     [Google Scholar]
  4. SiegelR.L. MillerK.D. JemalA. Cancer statistics, 2019.CA Cancer J. Clin.201969173410.3322/caac.21551 30620402
     [Google Scholar]
  5. PlanchardD. BesseB. GroenH.J.M. HashemiS.M.S. MazieresJ. KimT.M. QuoixE. SouquetP.J. BarlesiF. BaikC. VillaruzL.C. KellyR.J. ZhangS. TanM. GasalE. SantarpiaL. JohnsonB.E. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis.J. Thorac. Oncol.202217110311510.1016/j.jtho.2021.08.011 34455067
     [Google Scholar]
  6. RothJ.A. CarlsonJ.J. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis.Clin. Lung Cancer201112639340110.1016/j.cllc.2011.04.005 21723790
     [Google Scholar]
  7. KeshariS. BarrodiaP. SinghA.K. Epigenetic Perspective of Immunotherapy for Cancers.Cells202312336510.3390/cells12030365 36766706
     [Google Scholar]
  8. McCarthyF. RoshaniR. SteeleJ. HagemannT. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).J. Leukoc. Biol.20139461201120610.1189/jlb.0313121 23695306
     [Google Scholar]
  9. XiaL. LiuY. WangY. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.Oncologist201924S1Suppl. 1S31S4110.1634/theoncologist.2019‑IO‑S1‑s05 30819829
     [Google Scholar]
  10. PassigliaF. GalvanoA. RizzoS. IncorvaiaL. ListìA. BazanV. RussoA. Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.Int. J. Cancer201814261277128410.1002/ijc.31136 29080213
     [Google Scholar]
  11. WeberJ.S. KählerK.C. HauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab.J. Clin. Oncol.201230212691269710.1200/JCO.2012.41.6750 22614989
     [Google Scholar]
  12. BhardwajM. ChiuM.N. Pilkhwal SahS. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: Pathogenesis, treatment, and surveillance.Cutan. Ocul. Toxicol.2022411739010.1080/15569527.2022.2034842 35107396
     [Google Scholar]
  13. KawsarA. EdwardsC. PatelP. HeywoodR.M. GuptaA. MannJ. HarlandC. HeelanK. LarkinJ. LoriganP. HarwoodC.A. MatinR.N. FearfieldL. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: A multicentre observational study.Br. J. Dermatol.2022187698198710.1111/bjd.21836 35976170
     [Google Scholar]
  14. ZhangY.C. ZhuT.C. NieR.C. LuL.H. XiangZ.C. XieD. LuoR.Z. CaiM.Y. Association between early immune-related adverse events and survival in patients treated with PD-1/PD-L1 inhibitors.J. Clin. Med.202312373610.3390/jcm12030736 36769385
     [Google Scholar]
  15. CortelliniA. BersanelliM. SantiniD. ButiS. TiseoM. CannitaK. PerroneF. GiustiR. De TursiM. ZorattoF. MarconciniR. RussanoM. ZeppolaT. AnesiC. FilettiM. MarchettiP. BotticelliA. GelibterA. De GalitiisF. VitaleM.G. RastelliF. TudiniM. SilvaR.R. AtzoriF. ChiariR. RicciutiB. De GiglioA. MigliorinoM.R. MallardoD. VanellaV. MosilloC. BracardaS. RinaldiS. BerardiR. NatoliC. FicorellaC. PorzioG. AsciertoP.A. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.Eur. J. Cancer2020128172610.1016/j.ejca.2019.12.031 32109847
     [Google Scholar]
  16. AhnB.C. PyoK.H. XinC.F. JungD. ShimH.S. LeeC.Y. ParkS.Y. YoonH.I. HongM.H. ChoB.C. KimH.R. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.J. Cancer Res. Clin. Oncol.201914561613162310.1007/s00432‑019‑02899‑y 30911841
     [Google Scholar]
  17. StroupD.F. BerlinJ.A. MortonS.C. OlkinI. WilliamsonG.D. RennieD. MoherD. BeckerB.J. SipeT.A. ThackerS.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.JAMA2000283152008201210.1001/jama.283.15.2008 10789670
     [Google Scholar]
  18. HigginsJ.P. Cochrane handbook for systematic reviews of interventions.2011Available from: www. cochrane-handbook. org
    [Google Scholar]
  19. WellsG.A. SheaB.O. ConnellD. PetersonJ. WelchV. LososM. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.2000Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
    [Google Scholar]
  20. HigginsJ.P.T. ThompsonS.G. Quantifying heterogeneity in a meta‐analysis.Stat. Med.200221111539155810.1002/sim.1186 12111919
     [Google Scholar]
  21. AsoM. ToiY. SugisakaJ. AibaT. KawanaS. SaitoR. OgasawaraT. TsurumiK. OnoK. ShimizuH. DomekiY. TerayamaK. KawashimaY. NakamuraA. YamandaS. KimuraY. HondaY. SugawaraS. Association between skin reaction and clinical benefit in patients treated with anti‐programmed cell death 1 monotherapy for advanced non‐small cell lung cancer.Oncologist2020253e536e54410.1634/theoncologist.2019‑0550 32162801
     [Google Scholar]
  22. CortelliniA. ChiariR. RicciutiB. MetroG. PerroneF. TiseoM. BersanelliM. BordiP. SantiniD. GiustiR. GrassadoniaA. Di MarinoP. TinariN. De TursiM. ZorattoF. VeltriE. MalorgioF. GarufiC. RussanoM. AnesiC. ZeppolaT. FilettiM. MarchettiP. BerardiR. RinaldiS. TudiniM. SilvaR.R. PiredduA. AtzoriF. IaconoD. MigliorinoM.R. PorzioG. CannitaK. FicorellaC. ButiS. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients.Clin. Lung Cancer2019204237247.e110.1016/j.cllc.2019.02.006 30885550
     [Google Scholar]
  23. BernerF. BomzeD. DiemS. AliO.H. FässlerM. RingS. NiedererR. AckermannC.J. BaumgaertnerP. PikorN. CruzC.G. van de VeenW. AkdisM. NikolaevS. LäubliH. ZippeliusA. HartmannF. ChengH.W. HöngerG. RecherM. GoldmanJ. CozzioA. FrühM. NeefjesJ. DriessenC. LudewigB. HegazyA.N. JochumW. SpeiserD.E. FlatzL. Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer.JAMA Oncol.2019571043104710.1001/jamaoncol.2019.0402 31021392
     [Google Scholar]
  24. HarataniK. HayashiH. ChibaY. KudoK. YonesakaK. KatoR. KanedaH. HasegawaY. TanakaK. TakedaM. NakagawaK. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer.JAMA Oncol.20184337437810.1001/jamaoncol.2017.2925 28975219
     [Google Scholar]
  25. CortelliniA. FriedlaenderA. BannaG.L. PorzioG. BersanelliM. CappuzzoF. AertsJ.G.J.V. GiustiR. BriaE. CortinovisD. GrossiF. MigliorinoM.R. GalettaD. PassigliaF. BerardiR. MazzoniF. Di NoiaV. SignorelliD. TuziA. GelibterA. MarchettiP. MacerelliM. RastelliF. ChiariR. RoccoD. InnoA. Di MarinoP. MansuetoG. ZorattoF. SantoniM. TudiniM. GhidiniM. FilettiM. CatinoA. PizzutiloP. SalaL. OcchipintiM.A. CitarellaF. RussanoM. TorniaiM. CantiniL. FolladorA. SforzaV. NigroO. FerraraM.G. D’ArgentoE. LeonettiA. PettorutiL. AntonuzzoL. ScodesS. LandiL. GuaitoliG. BaldessariC. BertoliniF. Della GravaraL. Dal BelloM.G. BelderbosR.A. De FilippisM. CecchiC. RicciardiS. DonisiC. De TomaA. ProtoC. AddeoA. CantaleO. RicciutiB. GenovaC. MorabitoA. SantiniD. FicorellaC. CannitaK. Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes.Clin. Lung Cancer2020216498508.e210.1016/j.cllc.2020.06.010 32680806
     [Google Scholar]
  26. HosoyaK. FujimotoD. MorimotoT. KumagaiT. TamiyaA. TaniguchiY. YokoyamaT. IshidaT. HiranoK. MatsumotoH. KominamiR. TomiiK. SuzukiH. HirashimaT. UchidaJ. MoritaM. KanazuM. SawaN. MakioT. HaraS. TamiyaM. Association between early immune-related adverse events and clinical outcomes in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.Clin. Lung Cancer2020214e315e32810.1016/j.cllc.2020.01.003 32113737
     [Google Scholar]
  27. MorimotoK. YamadaT. TakumiC. OguraY. TakedaT. OnoiK. ChiharaY. TaniguchiR. YamadaT. HiranumaO. MorimotoY. IwasakuM. KanekoY. UchinoJ. TakayamaK. Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: A retrospective study.Front. Oncol.20211163013610.3389/fonc.2021.630136 33833990
     [Google Scholar]
  28. NaqashA.R. RicciutiB. OwenD.H. FlorouV. ToiY. CherryC. HafizM. De GiglioA. MuzaffarM. PatelS.H. SugawaraS. BurkartJ. ParkW. ChiariR. SugisakaJ. OttersonG.A. de Lima LopesG. WalkerP.R. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: A pooled exploratory analysis from a global cohort.Cancer Immunol. Immunother.20206971177118710.1007/s00262‑020‑02536‑5 32140762
     [Google Scholar]
  29. RicciutiB. GenovaC. De GiglioA. BassanelliM. Dal BelloM.G. MetroG. BrambillaM. BaglivoS. GrossiF. ChiariR. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: Long-term outcomes from a multi-institutional analysis.J. Cancer Res. Clin. Oncol.2019145247948510.1007/s00432‑018‑2805‑3 30506406
     [Google Scholar]
  30. TeraokaS. FujimotoD. MorimotoT. KawachiH. ItoM. SatoY. NagataK. NakagawaA. OtsukaK. UeharaK. ImaiY. IshidaK. FukuokaJ. TomiiK. Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: A Prospective Cohort Study.J. Thorac. Oncol.201712121798180510.1016/j.jtho.2017.08.022 28939128
     [Google Scholar]
  31. YonedaT. SoneT. KobaH. ShibataK. SuzukiJ. TaniM. NishitsujiM. NishiK. KobayashiT. ShirasakiH. ArayaT. KitaT. KaseK. YamamuraK. TeradaN. NishikawaS. TamboY. KimuraH. KasaharaK. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings.Clin. Lung Cancer202223646747610.1016/j.cllc.2022.03.008 35618628
     [Google Scholar]
  32. TangK. SeoJ. TiuB.C. LeT.K. PahalyantsV. RavalN.S. Ugwu-DikeP.O. ZubiriL. NaranbhaiV. CarringtonM. GusevA. ReynoldsK.L. LeBoeufN.R. AsgariM.M. KwatraS.G. SemenovY.R. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 therapy.JAMA Dermatol.2022158218919310.1001/jamadermatol.2021.5476 35019948
     [Google Scholar]
  33. SibaudV. Dermatologic reactions to immune checkpoint inhibitors.Am. J. Clin. Dermatol.201819334536110.1007/s40257‑017‑0336‑3 29256113
     [Google Scholar]
  34. SchulzT.U. ZieroldS. SachseM.M. PeschG. TomsitzD. SchilbachK. KählerK.C. FrenchL.E. HeinzerlingL. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life.Eur. J. Cancer2022176889910.1016/j.ejca.2022.08.029 36198246
     [Google Scholar]
  35. NikolaouV.A. ApallaZ. CarreraC. FattoreD. SollenaP. RigantiJ. SeguraS. Freites-MartinezA. LallasK. RomanoM.C. OikonomouC. StaraceM. DimopoulosM.A. KyrgidisA. LazaridouE. GiavedoniP. AnnunziataM.C. PerisK. EcheverríaM. Lopez-TujilloE. SyrigosK. PapageorgiouC. PodlipnikS. FabbrociniG. TorreA.C. KemanetziC. Villa-CrespoL. LallasA. StratigosA.J. SibaudV. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: A multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.Br. J. Dermatol.2022187696296910.1111/bjd.21781 35861701
     [Google Scholar]
  36. WangL.L. PatelG. Chiesa-FuxenchZ.C. McGettiganS. SchuchterL. MitchellT.C. MingM.E. ChuE.Y. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy.JAMA Dermatol.201815491057106110.1001/jamadermatol.2018.1912 30027278
     [Google Scholar]
  37. MuntyanuA. NetchiporoukE. GersteinW. GniadeckiR. LitvinovI.V. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management.J. Cutan. Med. Surg.2021251597610.1177/1203475420943260 32746624
     [Google Scholar]
  38. HaanenJ.B.A.G. CarbonnelF. RobertC. KerrK.M. PetersS. LarkinJ. JordanK. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol.201829iv264iv26610.1093/annonc/mdy162
     [Google Scholar]
  39. LiuY. TangJ. YuL.Y. Jiang, Q Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.EXPLORE 202319573073510.1016/j.explore.2023.02.008
     [Google Scholar]
  40. TarhiniA.A. KangN. LeeS.J. HodiF.S. CohenG.I. HamidO. HutchinsL.F. SosmanJ.A. KlugerH.M. ErogluZ. KoonH.B. LawrenceD.P. KendraK.L. MinorD.R. LeeC.B. AlbertiniM.R. FlahertyL.E. PetrellaT.M. StreicherH. SondakV.K. KirkwoodJ.M. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.J. Immunother. Cancer202195e00253510.1136/jitc‑2021‑002535 33963015
     [Google Scholar]
  41. GarrettN.F.M.S. da CostaA.C.C. DamianiG. VasquesC.I. Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities.Crit. Rev. Oncol. Hematol.202015210298310.1016/j.critrevonc.2020.102983 32570149
     [Google Scholar]
/content/journals/cchts/10.2174/0113862073267261231106093845
Loading
Association of CirAEs and Efficacy in NSCLC Patients Treated with PD-1/PD-L1: A Meta-analysis of Cohort Studies
Comb Chem High Throughput Screen 28, 435 (2025); https://doi.org/10.2174/0113862073267261231106093845
/content/journals/cchts/10.2174/0113862073267261231106093845
/content/journals/cchts/10.2174/0113862073267261231106093845
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): cutaneous immune-related adverse events; ICis; Non-small cell lung cancer; ORR; OS; PD-1/PD-L1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test